None
Quote | AbbVie Inc. (NYSE:ABBV)
Last: | $185.16 |
---|---|
Change Percent: | -0.7% |
Open: | $183.45 |
Close: | $185.16 |
High: | $186.85 |
Low: | $182.11 |
Volume: | 6,934,769 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | AbbVie Inc. (NYSE:ABBV)
2024-07-26 11:18:45 ET More on AbbVie AbbVie Inc. (ABBV) Q2 2024 Earnings Call Transcript AbbVie: Why I Sold My Shares At $175 AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note Cerevel gains as AbbVie says it expects deal to close ...
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire The marketing authorization for SKYRIZI ® (risankizumab) marks its fourth approved indication ...
Message Board Posts | AbbVie Inc. (NYSE:ABBV)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ABBV News Article - AbbVie Stock Plunged: Should You Buy the Dip? | whytestocks | investorshangout | 05/01/2023 7:35:47 PM |
$ABBV reports 1Q23 resultsraises non-GAAP EPS guidance: | DewDiligence | investorshub | 04/27/2023 12:00:28 PM |
$ABBVFDA expands Qulipta label_to prevention of chronic migraine: | DewDiligence | investorshub | 04/18/2023 6:23:32 PM |
Skyrizi phase-3 in UC hits all endpoints: | DewDiligence | investorshub | 03/23/2023 2:02:00 PM |
$ABBV advances Rinvoq to phase-3 in lupus: | DewDiligence | investorshub | 03/23/2023 2:00:38 PM |
News, Short Squeeze, Breakout and More Instantly...
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire The marketing authorization for SKYRIZI ® (risankizumab) marks its fourth approved indication ...
A look at the top 10 most actives in Canada Royal Bank of Canada (RY) fell 0.5% to $151.52 on volume of 20,132,699 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 8.1% to $2.61 on volume of 12,707,336 shares Veren Inc. (VRN) fell 2.4% to $10.24 on volume of 12,342,239 share...
2024-07-25 16:25:02 ET AbbVie (NYSE: ABBV) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in late-session action. This occurred in the wake of the company's...